NCT04224818View on ClinicalTrials.gov

Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

August 20, 2019

Study Completion Date

August 30, 2019

Conditions
Poor Ovarian Reserve
Interventions
DRUG

Dual trigger

Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)

DRUG

hCG (standard)

human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)

Trial Locations (1)

Unknown

American University of Beirut Medical Center, Beirut

All Listed Sponsors
lead

American University of Beirut Medical Center

OTHER

NCT04224818 - Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders | Biotech Hunter | Biotech Hunter